MEDIAN Technologies

Managing mRECIST Criteria in Oncology Clinical Trials

MEDIAN Technologies

Published on:2013年 11月 19日 火曜日
Length:6 Pages
Type: white papers

mRECIST is now recommended by the European Association for the Study of the Liver(EASL) for clinical studies on advanced hepatocellular carcinoma (HCC) as it better fits disease evolution assessment than standard RECIST does.However, mRECIST for HCCis more complex than RECIST. Its management in clinical trials raises specific issues and challenges regarding image acquisition, assessment, and reporting. Tackling these issues would maximize the expected benefits of mRECIST implementation, leading to an accurate assessment of drug efficacy in advanced HCC using imaging endpoints. This paper provides a review of imaging challenges to be considered when implementing mRECIST and describes MEDIAN’s innovative approach for managing mRECIST, based on the actual case of a successful phase II clinical trial.

Fill in form to download now!

Title *
Company / organisation *
Firstname *
Job title *
Lastname *
City *
E-mail *
Country *

All information that you supply is protected by our privacy policy.
In order to provide you with this free service, we may share your business information with companies whose content you choose to view on this website.
By submitting your information you agree to our Terms of Use. - See more at: IMAIOS privacy policy

Other papers that might interest you

To feature here :  Get in touch